LOBEF
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.01 | $0 | -$2M |
| 2025 Q1 | -0.00 | $0 | -$578,338 |
| 2025 Q4 | -0.01 | $0 | -$398,339 |
| 2025 Q3 | -0.01 | $0 | -$408,208 |
| 2025 Q2 | -0.00 | $0 | -$367,239 |
| 2024 Q1 | -0.01 | $0 | -$243,068 |
| 2024 Q4 | -0.02 | $0 | -$14,259 |
| 2024 Q3 | -0.00 | $0 | -$321,981 |